Regional heritability mapping method helps explain missing heritability of blood lipid traits in isolated populations

M Shirali1, R Pong-Wong2, P Navarro1, S Knott3, C Hayward1, V Vitart1, I Rudan4,5, H Campbell5, ND Hastie1, AF Wright1 and CS Haley1,2

Single single-nucleotide polymorphism (SNP) genome-wide association studies (SSGWAS) may fail to identify loci with modest effects on a trait. The recently developed regional heritability mapping (RHM) method can potentially identify such loci. In this study, RHM was compared with the SSGWAS for blood lipid traits (high-density lipoprotein (HDL), low-density lipoprotein (LDL), plasma concentrations of total cholesterol (TC) and triglycerides (TG)). Data comprised 2246 adults from isolated populations genotyped using ~300 000 SNP arrays. The results were compared with large meta-analyses of these traits for validation. Using RHM, two significant regions affecting HDL on chromosomes 15 and 16 and one affecting LDL on chromosome 19 were identified. These regions covered the most significant SNPs associated with HDL and LDL from the meta-analysis. The chromosome 19 region was identified in our data despite the fact that the most significant SNP in the meta-analysis (or any SNP tagging it) was not genotyped in our SNP array. The SSGWAS identified one SNP associated with HDL on chromosome 16 (the top meta-analysis SNP) and one on chromosome 10 (not reported by RHM or in the meta-analysis and hence possibly a false positive association). The results further confirm that RHM can have better power than SSGWAS in detecting causal regions including regions containing crucial ungenotyped variants. This study suggests that RHM can be a useful tool to explain some of the ‘missing heritability’ of complex trait variation.

INTRODUCTION

Blood lipoprotein concentration is an important risk factor for coronary heart disease and stroke (Lewington et al., 2007). The main lipoproteins in blood include high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels and plasma concentrations of total cholesterol (TC) and triglycerides (TG). These traits have moderate to high heritability: 40–60% for HDL, 40–50% for LDL, 35–48% for TG (Weiss et al., 2006; Kathiresan et al., 2007) and 41–53% for TC (Bielsinska et al., 2006; Velasquez-Melendez et al., 2007). Large meta-analysis (Teslovich et al., 2010; Surakka et al., 2015) of genome-wide association studies (GWAs) in blood lipid traits uncovered associations explaining only a fraction of the heritabilities of these traits. In most GWAs, single single-nucleotide polymorphism (SNP) analysis (SSGWAS) has been used to determine associated variants and subsequently their contribution to complex trait variation. This method has been shown to lack power for the detection of rare genetic variants (Bodmer and Tomlinson, 2010) because of low linkage disequilibrium between rare alleles and genotyped SNPs on the SNP genotyping array (Zeggini et al., 2005). Nagamine et al. (2012b) suggested that the regional heritability mapping (RHM) method can uncover genetic variance not identified by SSGWAS. The RHM method uses a relationship matrix between individuals based on SNP information from short regions of genome to estimate the trait variance explained by each region and localize variation. The main objective of this method is to uncover the variance contributed by the combined effect of both common and rare alleles in a region that may be missed by the SSGWAS scan. Uemoto et al. (2013) demonstrated the advantage in power of RHM in comparison with SSGWAS and some gene-based association methods, such as versatile gene-based association study (Liu et al., 2010), SNP-set (Sequence) Kernel Association Test (Wu et al., 2011) and canonical correlation analysis (Tang and Ferreira, 2012), using simulations based on real genotype data from a human population and a wide range of scenarios for quantitative trait loci (QTLs) with both common and rare alleles. Uemoto et al. (2013) demonstrated that the power of RHM to detect QTL is greater than the other methods studied, with causative variants at both low (0.0005 < MAF < 0.10) and high (MAF > 0.10) minor allele frequencies (MAFs). They reported that the power of these gene-based association methods was strongly affected by the QTL MAF. For example, the power of versatile gene-based association study decreased for the detection of low MAF QTLs, whereas that of SNP-set (Sequence) Kernel Association Test, which was developed as a rare-variant association test (Wu et al., 2011), was reduced for high MAF QTLs (Uemoto et al., 2013). Other region-based analyses that account for familial data structure may be similar to RHM in power. For example, SNP-set (Sequence) Kernel Association Test power can be improved by changing the β-weights (Belonogova et al., 2013), and

1MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; 2Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, UK; 3Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK; 4Croatian Centre for Global Health, Faculty of Medicine, University of Split, Split, Croatia and 5Centre for Population Health sciences, University of Edinburgh, Edinburgh, UK

Correspondence: Professor CS Haley, MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2UX, UK.

E-mail: Chris.Haley@rm.ed.ac.uk

Received 13 May 2015; revised 23 October 2015; accepted 26 October 2015; published online 23 December 2015
specific family-based versions of the approach are also available (Chen et al., 2013; Svishcheva et al., 2014).

The aims of this study were to identify regions and SNPs that contribute to variation in blood lipid traits using RHM and SSGWAS analysis in three isolated Croatian populations and to compare the effectiveness of the RHM approach in capturing the heritability of blood lipid traits with SSGWAS in these populations. We compared our results with those of a large meta-analysis for validation.

MATERIALS AND METHODS

Populations, phenotypic and genotypic data

A total of 2246 adult volunteers from three Southern European populations in the city of Split and the islands of Vis and Korcula on the Dalmatian coast of Croatia participated in 3 epidemiological field studies. All cohort studies were approved by the Ethical Committee of the Medical School, University of Zagreb and the Multi-Centre Research Ethics Committee for Scotland. All participants gave written informed consent. Fasting plasma levels of four blood lipid traits (LDL, HDL, TC and TG) were recorded. Supplementary Table 1 presents the phenotypic mean, s.d. and sample size for each of four traits in these populations. Before merging the data together, each population was adjusted for the fixed effects, sex, age and age squared by fitting a linear regression model and the residuals were rank transformed to the standard normal distribution, separately. The adjusted and rank-transformed data were used as the phenotypes for both SSGWAS and RHM analysis.

The samples were genotyped using 300K SNP genotyping arrays (Illumina Human Hap500 for Vis and Illumina Inc. (San Diego, CA, USA) CNV570 for Korcula and Split). Quality control procedures were performed per SNP and per individual. SNPs with MAF < 0.001, Hardy–Weinberg equilibrium (P<10^-8) and call rate < 0.98 were discarded. Individuals were excluded with a call rate of <0.98. After these quality control stages, 2246 individuals remained, and 268 651 autosomal SNPs were common to all the population samples and were used in our analysis. Genotypic quality control was done using the GenABEL library version 1.6-5 (Aulchenko et al., 2007) in R (R Development Core Team, 2011, Vienna, Austria, version 2.12.2).

Statistical analysis

Single SNP genome-wide association method. For all four traits, SSGWAS analysis was performed using the GenABEL package in the R environment. The whole genome kinship matrix was constructed using pair-wise identities by state of all autosomal SNPs in the data set that passed the quality control criteria using the lgs function of GenABEL (option weight = ‘freq’ as described by Aulchenko et al. (2007). The association test was performed fitting the whole genome kinship matrix as a random effect to account for relatedness using the polygenic and mmscore functions of GenABEL (Chen and Abecasis, 2007) in R.

RHM analysis method.

In the RHM method, the genome was divided into regions using sequential windows of genotyped markers to assess the contribution from each region to the trait variance. A random effects model was applied to the adjusted and rank-transformed phenotypes. For this study two random effects were included: the regional genomic polygenic and whole genome polygenic matrices, as described by Nagamine et al. (2012b), using the ASReml software (Gilmour et al., 2002). To evaluate the evidence for a regional heritability > 0, for each window, a likelihood ratio test statistic compared the full model including a regional effect with the null model (no regional heritability) that just included the relationship matrix derived using all autosomal SNPs in the data set that passed the quality control criteria. The full model and the null model are as below:

Full Model: $y = 1_{n \times 1} \beta + Z_{n \times a} \alpha + Z_{n \times r} r + \epsilon$

Null Model: $y = 1_{n \times 1} \beta + Z_{n \times a} \alpha + \epsilon$

where $y$ represents the adjusted and rank-transformed phenotype of interest, $n$ is the number of individuals, $\mu$ is the overall mean, $a$ is the whole genome additive genetic effect, matrix $Z_a$ is the whole genome relatedness matrix, $r$ is the regional additive genetic effect, matrix $Z_r$ is the regional relatedness matrix and $\epsilon$ is the vector of residuals. The regional and whole genome genetic values were estimated using a relationship matrix derived from markers as described by Nagamine et al. (2012a) by using the formulae below:

$$f_{i,j} = \frac{2 \sum_{k=1}^{m} (g_{ik} - p_{ik})(g_{jk} - p_{jk})}{p_{ik}(1 - p_{ik})}, \quad (i \neq j)$$

$$f_{i,i} = 1 + \frac{\sum_{j=1}^{m} \text{Obs}(\#\text{hom})_{ij} - \text{E}(\#\text{hom})_{ij}}{1 - \text{E}(\#\text{hom})_{ij}}, \quad (i = j)$$

where $f_{i,j}$ is the genomic relationship between individuals $i$ and $j$, $g_{ik}$ is the genotype of the individual $i$ at the k-th SNP (coded as 0, 0.5 and 1, for AA, BA and BB, respectively), $p_i$ is the frequency of the allele B of k-th SNP and $m$ is the number of SNPs used for relationship estimation, representing the total number of autosomal SNPs for the whole genome relationship matrix or the number of SNPs in the region for the regional genomic relationship matrix. Obs(\#hom)$_{ij}$ and E(\#hom)$_{ij}$ are the observed number and expected number of homozygous genotypes under Hardy–Weinberg equilibrium at the k-th SNP. Whole genomic, regional genomic and residual variances were $\sigma^2_w$, $\sigma^2_r$ and $\sigma^2_e$, respectively. The variance of the adjusted and rank-transformed phenotype of interest, $\sigma^2_y$, was calculated as $\sigma^2_y = \sigma^2_w + \sigma^2_r + \sigma^2_e$ and therefore the whole genome and regional heritabilities were $h^2_w = \sigma^2_w/\sigma^2_y$ and $h^2_r = \sigma^2_r/\sigma^2_y$, respectively.

In the RHM analyses, the genome was scanned using regions (windows) spanning 100 consecutive genotyped SNPs. Between the sequential windows we allowed for a 50-SNP overlap as explained by Nagamine et al. (2012b). Using the relationship matrix obtained from the SNPs within a window enables the contribution of this region to the trait variance to be estimated and regions affecting the trait to be identified. To fine-map associated variants, the top 100 windows based on likelihood ratio test statistic values of 100-SNP window tests were further analyzed using sequential 10-SNP windows with 5-SNP overlap. This potentially allows narrow down the regions of the genome associated with the trait of interest.

Significance thresholds. To determine the significance thresholds for SSGWAS and RHM, a Bonferroni correction based on the number of independent tests performed in each scenario was used to obtain a genome-wide 5% significance threshold. In the SSGWAS method, this gave a $-\log P$-value threshold of 6.73, as 268 651 autosomal SNPs were used in this analysis. For the RHM method, in 100-SNP windows with 50-SNP overlap and 10-SNP windows with 5-SNP overlap, 5373 and 53 732 windows were tested, respectively, and half that number was used to estimate the Bonferroni corrected significance thresholds and account for overlapping windows (as described by Nagamine et al., 2012b). This resulted in thresholds of 4.73 $-\log P$-value for 100-SNP windows with 50-SNP overlap, and 5.73 $-\log P$-value for 10-SNP windows with 5-SNP overlap. To balance between type I and type II errors, we considered the suggestive level of significance, defined as the level at which one false positive per genome scan is expected (Rao and Gu, 2001). The genome-wide suggestive significance thresholds obtained using Bonferroni correction were 5.43, 4.43 and 3.43 $-\log P$-values for SSGWAS, 10-SNP and 100-SNP windows, respectively.

RESULTS

High-density lipoprotein

Figure 1 shows the Manhattan plot for HDL using the SSGWAS method. Three SNPs associated with HDL were detected by SSGWAS at the 5% significance level after Bonferroni correction. Two of these variants (‘rs7499892’ and ‘rs3764261’) were close together on chromosome 16 and the third SNP (‘rs3758562’) on chromosome 10. Furthermore, a SNP on chromosome 15 (‘rs1332085’) was significant at the suggestive level after Bonferroni correction. Supplementary Table 2 presents SSGWAS results for 10 top SNPs with the $-\log P$-value of $>5.00$ for HDL.

Using the RHM method, the estimated heritability of HDL over the whole genome (estimated by averaging the whole genome heritabilities across all 100-SNP windows) was 45.8% (s.e. 6.6%). Two significant windows associated with HDL were detected using the 100-SNP window analysis at the 5% significance level after Bonferroni

Heredity
correction, one on chromosome 15 and the other on chromosome 16 (Table 1). Fine-mapping RHM analysis (using 10-SNP windows) of the associated region on chromosome 15 showed that the region with 3.5% heritability contains the SNP (‘rs1532085’) that was suggestive and not genome-wide significant in the SSGWAS analysis. In addition, fine-mapping of the significant region on chromosome 16 indicated that the window contains two significant overlapping 10-SNP windows. The region covering these two overlapping 10-SNP windows each with 4.0% heritability harbors the SNP ‘rs3764261’ identified by SSGWAS. Supplementary Table 3 presents RHM results for 10 top 100-SNP windows for all traits of interest.

**Low-density lipoprotein**

Using SSGWAS, no SNP associated with LDL was detected at the genome-wide significance level. The estimated heritability of LDL averaged over the RHM genome scan using 100-SNP windows was 47.4% (s.e. 6.5%). RHM identified a region on chromosome 19 from 49455904 to 50999246 base pair associated with LDL. This region encompassed two genome-wide significant overlapping 100-SNP windows explaining 4.8% and 6.2% of the trait variance for LDL, respectively. The fine-mapping analysis using 10-SNP windows narrowed the region down to a single 10-SNP region with an estimated 7.3% heritability.

**DISCUSSION**

**RHM vs SSGWAS**

Table 2 presents the estimated variances of the significant SNPs detected by the SSGWAS method and their regional variance estimated by the RHM method compared with the SNP variances suggested by meta-analysis. On chromosome 10, the significant SNP (‘rs3758562’) identified by SSGWAS to be associated with HDL was not confirmed by the RHM method as the region containing this SNP was not significantly associated. This SNP and the region containing it was also not detected in the meta-analysis of Teslovich et al. (2010) and in the most current meta-analysis report in HDL by Surakka et al. (2015) and also no report was found for any significant SNP around this region in GWAS catalog (http://www.genome.gov/gwastudies) for HDL. This result may suggest that SSGWAS detected a false positive and RHM method may have avoided this problem. Furthermore, on chromosome 15, the suggestive SNP (‘rs1532085’) by SSGWAS explained
Table 1. Genome-wide significant RHM with 100-SNP windows overlapping and result from top 10-SNP window in each region

| Trait     | Chr | Start | End   | SNP and position (bp) | LRT   | −log P-value | RH  |
|-----------|-----|-------|-------|-----------------------|-------|--------------|-----|
| HDL       | 16  | 81    | 229   | rs2291956 55 249       | 7.15  | 4.0%         |     |
|           | 15  | 66    | 56    | rs4646583 56 457       | 7.02  | 3.5%         |     |
| LDL       | 19  | 71    | 37    | rs2037131 19 860       | 11.91 | 7.3%         |     |

Abbreviations: Chr, chromosome; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LRT, likelihood ratio test; RH, regional heritability; RHM, regional heritability mapping.

**RHM and SSGWAS vs meta-analysis**

Table 3 presents comparisons between variance explained by meta-analysis, SSGWAS and RHM in the traits of interest. The meta-analysis identified 45 associated variants for HDL in addition to the two regions identified in this study. This is likely due in part to the sample size of the meta-analysis of > 100,000 individuals compared with 2246 individuals in the current study. In addition, 34 out of 47 SNPs associated with HDL in the meta-analysis were not genotyped in the current study.

We estimated that the heritability explained by the 47 loci detected in the meta-analysis would be 12.2% for HDL using reported MAFs and effects in the meta-analysis data set. In addition, 13 of these SNPs genotyped in the current study would explain 6.4% of the total variance of HDL. Although just one of the 13 SNPs available out of the 47 was significant in the SSGWAS in the current study, these loci together explained 4.4% of total trait variance for HDL. Using the RHM method, regions harboring these 13 SNPs explained 8.5% of the total trait variance for HDL in our data. The results suggest that the RHM method has the potential to explain a larger proportion of variance in traits than the SSGWAS method in the regions for which meta-analysis hits are available in our data set. For associating SNPs reported by meta-analysis that are available in our data set, the MAF in meta-analysis and estimated allele frequency in the current study is plotted in Supplementary Figure 1. For the other 34 regions for which the meta-analysis hits are not available in our data set, the regional heritability estimated by RHM was calculated; the total heritability of HDL explained by all 47 regions by RHM was 19.4%.

For LDL, the most significant region detected by RHM was that harboring the SNP (rs4420638) that was most significantly associated in the meta-analysis of Teslovich et al. (2010). This SNP was estimated to explain 2.3% of the variance for LDL based on the meta-analysis results. In the RHM analysis, the region containing this SNP explained an estimated 4.8% of the trait variance. Neither this SNP nor any SNP in high linkage disequilibrium (r² > 0.90) with it was genotyped in the current study; therefore, the region was not detected by SSGWAS. This confirms the analysis of Nagamine et al. (2012b) that the RHM method has the power to detect the associated regions, even if the associated variant is not genotyped in the data.

The 37 loci detected in meta-analysis explain 12.1% of total trait variance for LDL. Only 6 of the 37 SNPs were genotyped in the current study; therefore, the region was not detected by SSGWAS. This suggests that the RHM method performs better than the SSGWAS method in capturing the effective variants.

**Additional comments**

Missing heritability in blood lipid traits

Heredity

1.2% of total trait variance. However, the 100-SNP window containing this SNP was found to be highly significant by the RHM method, explaining 2.7% of total trait variance. Comparing these results with the meta-analysis of Teslovich et al. (2010) reveals that this SNP is one of the significantly associated variants with HDL with 0.9% heritability based on its reported allele frequency and estimated effect. This result indicates that the RHM method has the power to detect truly associated variants that may not reach the genome-wide significance level and hence may be missed by SSGWAS analysis. Finally, on chromosome 16, the SSGWAS analysis identified one significantly associated variant for HDL, ‘rs3764261’, explaining 2.0% of trait variance. The region harboring this SNP was captured by the RHM method as the most significant region associated with HDL, explaining 4.0% of trait variance and 8.7% of the total heritability. The meta-analysis further confirmed that ‘rs3764261’ is the most significant SNP associated with HDL with a −log P-value of 379.14; this SNP explained 4.5% of the trait variance based on its reported allele frequency and estimated effect in the meta-analysis. The current study suggests that the RHM method performs better than the SSGWAS method in capturing the effective variants.
study, and these explained 0.8% of total variance in meta-analysis, 0.8% using the SSGWAS method and 0.6% using the RHM method.

No significantly associated SNP or region was detected in the current study for either TC or TG. Teslovich et al. (2010) reported 52 and 32 associated loci for TC and TG, respectively, with estimated heritabilities explained by these loci of 12.4% and 9.6%. From these meta-analysis associated variants, only 12 and 4 SNPs, for TC and TG, respectively, were available in the current study. Based on the meta-analysis results, these SNPs explained 1.4% and 0.5% of the total trait variances for TC and TG, respectively. The SSGWAS study also suggested similar percentage of variance for these SNPs with 1.2% and 0.4% for TC and TG, respectively. The RHM method showed a higher percentage of variance for the regions containing these genotyped SNPs of 2.6% and 4.9% for TC and TG, respectively. However, using the RHM method, the 52 regions in TC and the 32 regions in TG that harbored associated variants as reported by Teslovich et al. (2010) explained 10.4% and 6.4% of trait variance in the current study compared with the meta-analysis of 12.4% and 9.4% for TC and TG, respectively.

CONCLUSION
Three significant regions detected by RHM provide evidence on the power of RHM under three different conditions. First, RHM can detect trait-associated regions that cannot be detected by the SSGWAS method by taking into account the nearby SNP effects. Second, this study suggests that when the SNP is not available in the data set, the RHM method can detect causative regions as this method uses effects of all SNPs in the region through the construction of a regional relationship matrix. Finally, the RHM method may be able to reduce the false discovery rate, a common problem with SSGWAS studies in populations that are characterized by a high inbreeding coefficient (Manenti et al., 2009) specially for SNPs with high MAF (Tabangin et al., 2009), by using nearby SNP information and the summation of SNP effects on a window.

DATA ARCHIVING
Summary statistics for SSGWAS and summary statistics for Regional Heritability Mapping are available from the Dryad Digital Repository: http://dx.doi.org/10.5061/dryad.6b65r. We have neither consent from individual participants nor appropriate ethical approval to permit full public release of data underlying this study. Researchers requiring access to the full data should contact Dr Caroline Hayward (caroline.hayward@igmm.ed.ac.uk).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by funding from the Medical Research Council (UK) and the Biotechnology and Biological Sciences Research Council (UK) (BBSRC reference: BB/300284/1). CROATIA-Korcula: the CROATIA-Korcula study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to Igor Rudan (108-1080315-0302). We acknowledge the invaluable contributions of the recruitment team in Korcula, the administrative teams in Croatia and Edinburgh and the people of Korcula. The SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum München, Neuherberg, Germany. CROATIA-Split: the CROATIA-Split study is funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to Igor Rudan (108-1080315-0302). We acknowledge the staff of several institutions in Croatia who supported the field work including, but not limited to, the University of Split and Zagreb Medical Schools and the Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Split cohort was performed by AROS Applied Biotechnology, Aarhus, Denmark. CROATIA-Vis: the CROATIA-Vis study was funded by grants from the Medical Research Council (UK) and Republic of Croatia Ministry of Science, Education and Sports research grants to Igor Rudan (108-1080315-0302). We acknowledge the staff of several institutions in Croatia who supported the field work including, but not limited

Table 2 Explained variance by SNP/region using meta-analysis, SSGWAS and RHM methods for captured SNPs

| Chromosome | SNP | Trait | Meta-analysis | SSGWAS | RHM |
|------------|-----|-------|---------------|--------|-----|
|            |     |       | $\sigma^2_A$  | $\sigma^2_S$ | $h^2_S$ | $h^2_A$ | $h^2_{win10}$ | $h^2_{win100}$ |
| 16         | rs3764261 | HDL    | 5.00          | 13.64       | 12.2%   | 4.5%    | 0.0%   | 4.0%    |
| 15         | rs1532085 | LDL    | 1.00          | 13.64       | 12.2%   | 0.9%    | 0.0%   | 3.5%    |
| 10         | rs3758562 | HDL    | NA            | 13.64       | 12.2%   | NA      | 1.3%   | 1.1% NS |
| 19         | rs4420638 | LDL    | 14.38         | 75.68       | 12.1%   | 2.3%    | NA     | 7.3%    |

Table 3 Variance comparison between meta-analysis, SSGWAS and RHM

| Method | HDL | LDL | TC | TG |
|--------|-----|-----|----|----|
|        | N_S | PVE | N_S | PVE |
| SSGWAS | 13  | 4.4%| 6  | 0.8%|
| RHM    | 47  | 19.4%| 37 | 12.4%|
|        | 13  | 8.5%| 6  | 0.6%|
|        | 13/47 | 43.8%| 6/37 | 2.3%|

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, number of SNPs; PVE, proportion of trait variance explained; RHM, regional heritability mapping; SNP, single-nucleotide polymorphism; SSGWAS, single SNP genome-wide association study; $\sigma^2_A$, explained variance by associating the SNP by meta-analysis that are available in our data set; $\sigma^2_S$, explained variance by the region containing the SNPs; $h^2_S$, explained trait heritability by all meta-analysis hits; $h^2_A$, explained heritability by the SNP; $h^2_{win10}$, heritability of the region using 10-SNP window by RHM method; $h^2_{win100}$, heritability of the region using 100-SNP window by RHM method.
AulchenkoYS, Ripke S, Isaacs A, van Duijn CM (2007). GenABEL: an R package for genome-wide association analysis. *Bioinformatics* **23**:1294–1296.

Belonogova NM, Svishcheva GR, van Duijn CM, Aulchenko YS, Axenovich TI (2013). Region-based association analysis of human quantitative traits in related individuals. *PLoS One* **8**: e65395.

Bielinski SJ, Tang WH, Pankow JS, Miller MB, Mosley TH, Boerwinkle E et al. (2006). Genome-wide linkage scans for loci affecting total cholesterol, HDL-C, and triglycerides: the Family Blood Pressure Program. *Hum Genet* **120**:371–380.

Bodmer W, Tomlinson I (2010). Rare genetic variants and the risk of cancer. *Curr Opin Genet Dev** **20**:262–267.

Chen H, Meigs JB, Dupuis J (2013). Sequence kernel association test for quantitative traits in family samples. *Genet Epidemiol** **37**:196–204.

Chen WM, Abecasis GR (2007). Family-based association tests for genome-wide association scans. *Am J Hum Genet** **81**:913–926.

Gilmour AR, Gogel BJ, Cullis BR, Welham SJ, Thompson R (2002). ASREML user guide, Release 1.0. Hemel Hempstead: VSN International.

Kathiresan S, Manning AK, Demissie S, D’Agostino, Srili A, Guiducci C et al. (2007). A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. *BMC Med Genet** **8**(Suppl 1): S17.

Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet* **370**:1829–1839.

Liu JZ, Mcrae AF, Nyholt DR, Medland SE, Wray NR, Brown KM et al. (2010). A versatile gene-based test for genome-wide association studies. *Am J Hum Genet** **87**:139–145.

Manenti G, Galvan A, Pettinato A, Trincucci G, Spada E, Zolin A et al. (2009). Mouse genome-wide association mapping needs linkage analysis to avoid false-positive loci. *PLoS Genet** **5**:e1000331.

Nagamine Y, Pong-Wong R, Navarro P, Shirali M, Uemoto Y, Huffman J et al. (2012a). Regional heritability mapping for the dissection of complex traits.

Nagamine Y, Pong-Wong R, Navarro P, Vitart V, Hayward C, Rudan I et al. (2012b). Localising loci underlying complex trait variation using regional genomic relationship mapping. *PLoS One** **7**:e46501.

Rao DC, Gu C (2001). False positives and false negatives in genome scans. *Adv Genet** **42**:487–498.

Surakka I, Horikoshi M, Mägi R, Sarin A, Mahajan DR, Lagou V et al. (2015). The impact of low-frequency and rare variants on lipid levels. *Nat Genet** **47**:589–597.

Svishcheva GR, Belonogova NM, Axenovich TI (2014). FFBSKAT: Fast Family-Based Sequence Kernel Association Test. *PLoS One** **9**:e99407.

Tabangin ME, Woo JG, Martin LJ (2009). The effect of minor allele frequency on the likelihood of obtaining false positives. *BMC Proc** **3**(Suppl 7): S41.

Tang CS, Ferreira MA (2012). A gene-based test of association using canonical correlation analysis. *Bioinformatics** **28**:845–850.

Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M et al. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. *Nature** **466**:707–713.

Uemoto Y, Pong-Wong R, Navarro P, Vitart V, Hayward C, Wilson JF et al. (2013). The power of regional heritability analysis for rare and common variant detection: simulations and application to eye biometrical traits. *Front Genet** **4**:232.

Velásquez-Meléndez G, Parra FC, Gazzinielli A, Williams-Blangero S, Corea-Oliveira R (2007). Genetic determinants of risk factors for cardiovascular disease in a population from rural Brazil. *Hum Biol** **79**:179–190.

Weiss LA, Pan L, Abney M, Ober C (2006). The sex-specific genetic architecture of quantitative traits in humans. *Nat Genet** **38**:218–222.

Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X (2013). Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet** **89**:82–93.

Zeggini E, Rayner W, Morris AP, Hattersley AT, Walker M, Hitman GA et al. (2005). An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data sets. *Nat Genet** **37**:1320–1322.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).